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Background: The chitinase-like protein YKL-40 is a serum biomarker in diseases with fibrosis,
inflammation and tissue remodelling. Idiopathic pulmonary fibrosis (IPF) is a progressive inter-
stitial lung disease that is hallmarked by these processes.
The aim of this study was to investigate the potential of YKL-40 as a prognostic biomarker for
survival in IPF patients.
Methods: Serum and bronchoalveolar lavage fluid (BALF) levels of YKL-40 at the time of diag-
nosis and a promoter polymorphism in CHI3L1, the gene encoding YKL-40, were determined in
85 IPF patients and 126 controls. The relationship between YKL-40 levels and clinical parame-
ters was evaluated. KaplaneMeier and Cox regression analyses were used to examine the asso-
ciation between YKL-40 levels and survival.
Results: Serum and BALF YKL-40 levels were significantly higher in patients than in healthy
controls (p < 0.001). The  329 A/G polymorphism had a significant influence on BALF YKL-
40 levels and the influence on serum YKL-40 levels showed a trend towards significance in
IPF patients. IPF patients with high (> 79 ng/ml) serum or high BALF YKL-40 (> 17 ng/ml) levels
had significantly shorter survival than those with low YKL-40 levels in serum or BALF. In patients
with both low serum and low BALF YKL-40 levels no IPF related mortality was observed. Cox
regression modelling showed that there were no confounding factors.Hospital, Department of Pulmonology, PO box 2500, 3430 EM Nieuwegein, The Netherlands. Tel.: þ31
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Serum and BALF YKL-40 levels predict survival in IPF 107Conclusions: The  329 polymorphism was associated with serum and BALF YKL-40 levels in IPF
patients. High serum and BALF YKL-40 levels are associated with poor survival in IPF patients
and could be useful prognostic markers for survival in IPF.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Idiopathic pulmonary fibrosis (IPF) is a rapidly progressing
disease that is characterized by remodelling of the lung
parenchyma. It’s aetiology remains unclear but tissue
remodelling in IPF is thought to be caused by pneumocyte
dysfunction, fibroblast proliferation, and chronic inflam-
mation.1,2,3 While the median survival time is only 2.5e3.5
years,4 survival can vary between a few months and
> 10 years. Although clinical trials show that some
improvement in lung function deterioration canbe achieved,
there is currently no therapy available that has a proven
long-termeffect on survival.5,6 Lung transplantation remains
the only option for those who qualify, but mortality on the
waiting list is high. To optimize the timing of referral for lung
transplantation, predictors of survival are needed.
YKL-40 is already a very promising biomarker for survival
in cancer.7 It is a member of the highly conserved family of
chitinases and chitinase-like proteins. Many of these
proteins are thought to play a role in inflammatory condi-
tions and asthma.8 YKL-40 binds chitin but lacks actual
chitinase activity. Its exact function remains unclear, but it
has been shown to stimulate fibroblast growth.9 In addition,
YKL-40 is elevated in inflammatory conditions and could be
involved in tissue remodelling.10,11,12,13,14,15
YKL-40 was recently shown to be elevated in the serum
and lungs of patients with IPF and immunohistochemistry
showed it to be expressed by alveolar epithelial cells and
alveolar macrophages near fibrotic lesions in these
patients.16 Elevated YKL-40 levels are also associated with
fibrotic lesions in several other diseases such as liver
cirrhosis, Crohn’s disease and systemic sclerosis.17,18,19 In
addition, serum YKL-40 levels are inversely correlated with
lung function in asthma, pulmonary sarcoidosis and IPF
patients.16,20,21 Genetic variations in CHI3L1, the gene
encoding YKL-40, have been associated with asthma
susceptibility and the extend of liver fibrosis.22,23 In healthy
individuals serum YKL-40 levels are substantially influenced
by polymorphisms in this gene.21
In our study, we measured pulmonary and circulating YKL-
40 levels in a cohort of IPF patients and assessed whether
YKL-40 concentrations were genotype dependent and could
be used as a prognostic biomarker for survival in IPF.
Methods
Subjects
The medical ethical committee of the St. Antonius Hospital
in Nieuwegein approved this study and all subjects gave
formal written informed consent. Patients who visited the
Centre for Interstitial Lung Diseases at the St. Antonius
Hospital, the Netherlands between November 1998 and 2009
were included (Table 1). Diagnoses made before 2002 werereviewed by a clinician and patients were only included
when the diagnosis met the criteria stated by the ATS/ERS in
2002.4 Other causes of UIP (drugs, collagen vascular
diseases) were ruled out and patients with proven familial
disease were excluded. In 54 patients (64%) the diagnosis
was confirmed by open lung biopsy and 22 patients were
treated with low-dose oral steroids. At the time of diag-
nosis, patients were asked to donate blood for DNA
extraction and for storage of serum samples. From 83 IPF
patients serum samples were available that were obtained
within 3 months after diagnosis. Bronchoalveolar lavage
fluid (BALF) was available from 60 IPF patients. Bron-
choalveolar lavage was performed in accordance with
previously described methods24 and all patients underwent
a lavage for diagnostic purposes. All samples were stored
at  80 C until analysis.
Our control group comprised 83 healthy employees of
the St. Antonius hospital and an additional independent
group of 43 healthy volunteers who underwent BAL.
Disease parameters
At presentation, IPF patients underwent lung function tests,
providing values for forced expiratory volume in 1 s (FEV1),
vital capacity (VC), FEV1/VC ratio, diffusion capacity of the
lungs for carbon monoxide (DLCO) and lung transfer coef-
ficient (KCO). Lung function parameters were available as
absolute values and as percentage of predicted values.
Patients were asked about their smoking habits and
smoking history and this was converted into a pack-year
value. Haematological differentiation was performed using
a cell counter (Coulter LH 750 Analyser, Beckman Coulter,
Fullerton, CA, USA).
Length of follow-up for survival was up to 4 years and
was based on hospital records. Patients that were still
alive, that were transplanted or died from a cause unre-
lated to IPF were censored in the survival analysis.
YKL-40 protein detection
YKL-40 levels were determined by YKL-40 enzyme immu-
noassay (Quidel Corporation, San Diego, CA, USA), which
was performed in accordance with the manufacturer’s
instructions. Twenty microliter of serum or BALF was used;
either undiluted or diluted 1:5 when exceeding the standard
curve range. The lower limit of quantitation of this ELISA is
15.6 ng/ml and the lower limit of detection is 5.4 ng/ml.
Genotyping
The  329 G > A promoter polymorphism, corresponding to
rs10399931 was analysed using sequence-specific primers as
previously described.21 This polymorphism was shown to
explain 23% of variation in serum YKL-40 levels in healthy
Table 1 Characteristics of patients and controls.
IPF patients Serum controls BALF controls
Number of subjects 85 83 43
Gender M/F 71/14 30/53 23/20
Age, yr 65  10 56  5 32  16
Smoking
Never 27 33 24
Former 52 34 2
Current 6 16 17
Pack year 18  12 NA NA
DLCO, % predicted 48  18 NA NA
FEV1, % predicted 82  23 NA 106  11
FVC, % predicted 78  23 NA 110  11
Blood monocytes, % 8  3 NA 8  2
Blood neutrophils, % 63  13 NA 56  8
Blood lymphocytes, % 24  11 NA 32  7
Blood eosinophils, % 4  2 NA 3  3
BALF macrophages, % 71  18 NA 88  10
BALF neutrophils % 10  12 NA 2  2
BALF YKL-40 level (Median, IQR) 12.3 (7.1e18.2) NA 4.8 (2.7e8.8)
Serum YKL-40 level (Median, IQR) 109.4 (76.6e237.7) 46.2 (32.7e71.3) 38.1 (33.3e51.6)
Data are presented as mean  SD unless otherwise indicated. NA, not available.
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morphism (rs4950928) at position  131 similarly influenced
the serum level of YKL-40 in controls.22,23 To investigate the
linkage between the two sites we retrieved the genotypes
from the Centre d’Etude du Polymorphisme Humain (CEPH)
population from the dbSNP database at http://www.ncbi.
nlm.nih.gov/. Linkage Disequilibrium between rs4950928
( 131) and rs10399931 ( 329) was calculated using Hap-
loview 4.0 software (Broad Institute, MIT, Cambridge, MA,
USA).25
Statistics
Serum and BALF YKL-40 levels are reported as median and
inter quartile range (IQR) and were natural log (ln)AG GG
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Figure 1 Serum YKL-40 levels in patients and healthy controls. In c
in the GG group (n Z 46) than in the AG group (n Z 25). The effec
(PZ 0.07).transformed during statistical analysis to correct for non-
Gaussian distributions. SPSS 15 (SPSS Inc., Chicago, IL, USA)
andGraphpad Prism v. 3 (Graphpad software INC., San Diego,
CA, USA) were used for statistical analysis. Spearman’s
rho test was used to assess the correlation between
serum YKL-40 concentrations and clinical parameters. The
KaplaneMeiermethodwith log-rank test was used to analyse
whether YKL-40 levels were associated with survival. The
optimal cut-off point between the two survival groups was
calculated with a ROC curve analysis. Cox regression analysis
with covariates was used to check for possible confounders
and to calculate a hazards ratio with 95% confidence interval
(CI). Pearson’s goodness-ofefit Chi-square test and Fisher’s
exact test were used to test for deviation from Har-
dyeWeinberg equilibrium and for a difference in genotypeAG GG
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Figure 2 BALF YKL-40 levels in patients and controls. BALF YKL-40 levels were not associated with genotype in controls. In
patients, BALF YKL-40 levels were significantly higher (P Z 0.01) in the GG group (n Z 28) than in the AG group (n Z 18).
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Figure 3 Correlation between Serum and BALF YKL-40 levels
in IPF patients (n Z 58). R2 Z 0.09 P < 0.05.
Serum and BALF YKL-40 levels predict survival in IPF 109and allele frequencies between patients and controls as
implemented online at http://ihg2.helmholtz-muenchen.
de/cgi-bin/hw/hwa1.pl.
Differences with a P value < 0.05 were considered
statistically significant.
Results
Clinical characteristics of patients and controls are
summarized in Table 1. Eighty-five patients with IPF (71
male and 14 female, mean age 65  10 years) were
included in this study.
Serum YKL-40 levels were significantly higher in IPF
patients than in controls (P < 0.0001) (Table 1). In healthy
controls, serum YKL-40 levels are genotype dependent
(P < 0.01) and a trend towards significance (p Z 0.07) was
observed in IPF patients (Fig. 1). The median serum YKL-40
level in patients with the 329 AG genotype was 89.3 ng/ml
(nZ 31, IQR 71.5e202.5) compared to 128.0 ng/ml (nZ 37,
IQR 85.9e198.4) in patients with the GG genotype.
BALF YKL-40 levels were also significantly elevated in IPF
patients compared to controls (P < 0.0001) (Table 1). In
patients, BALF YKL-40 levels were genotype dependent
(P Z 0.01, Fig. 2) but no difference was found in controls.
We did not find a relevant correlation between serum and
BALF YKL-40 levels (Fig. 3). The correlation between BALF
YKL-40 or serumYKL-40and lung functionparameterswas too
small to consider relevant. We found no effect of smoking,
steroid use or gender on serum or BALF YKL-40 levels.
Analysis of the genotype distribution in patients revealed
that there was no association with disease. We also found no
significant association between the CHI3L1 e329 genotype
and clinical parameters or survival. Linkage disequilibrium
between the 329 and the 131 promoter polymorphisms in
the CEPH-panel was high (D0 Z 1, r2Z 0.85).
Survival analysis: Serum YKL-40
Of the 83 patients with serum, follow-up was available from
79 patients. The median follow-up was 28.6 months. 42patients were still alive, six died from a cause unrelated to
IPF and three had undergone lung transplantation. ROC
curve analysis showed that the optimum cut-off point for
serum YKL-40 was 79 ng/ml, although there were several
other cut-off points that also resulted in a significant
difference on KaplaneMeier curves. The 4-year survival
rate in patients with serum YKL-40 level below 79 ng/ml
was 86% versus 48% in the group with higher serum YKL-40
levels (P < 0.01, Fig. 4 A). Multivariate Cox regression
analysis showed that age was also predictive for survival
but was not a confounding factor in our analysis. After
correction for age, gender, smoking, lung function and
blood cell counts, the hazard ratio for serum YKL-40 (cut-
off 79 ng/ml) was 10.9 (95%CI 1.9e63.8, p < 0.01).
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Figure 4 KaplaneMeier survival analysis grouped by baseline YKL-40 levels. Patients that were still alive, that were transplanted
or died from a cause unrelated to IPF were censored in the survival analysis. (A) Patients with high serum YKL-40 had significantly
worse survival estimates than patients with low serum YKL-40 (P < 0.01, c2 Z 6.77). (B) Patients with high BALF YKL-40 had
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Follow-up was available from 58 patients with BALF, of
whom 31 patients were still alive, five died from a cause
unrelated to IPF and two had undergone lung trans-
plantation. ROC-curve analysis showed that the optimum
cut-off point for BALF YKL-40 was 17 ng/ml. Patients with
a BALF YKL-40 level below 17 ng/ml had a significantly
better survival than patients with higher BALF YKL-40 levels
(P < 0.001, Fig. 4 B). The percentage of neutrophils in BALF
also showed a trend towards a significant association with
survival (p Z 0.06) but did not influence the association
between BALF YKL-40 levels and survival. After correction
for age, gender, smoking, lung function and BALF cell
counts the hazard ratio for BALF YKL-40 (cut-off 17 ng/ml)
was 3.0 (95%CI 1.1e8.4, p < 0.05).
Patients with the  329 GG genotype significantly more
often had BALF YKL-40 levels above 17 ng/ml than patients
with the AG genotype (11 of 28 patients versus 2 of 18
patients, respectively, p < 0.05). However, when we per-
formed KaplaneMeier analysis with the patients grouped
according to genotype, the difference was not significant
(P Z 0.5).
Combining the cut-off points for serum and BALF YKL-40
levels improved the predictive value of the KaplaneMeier
analysis and made it possible to stratify patients in three
groups (P Z 0.001, Fig. 4 C). Ten patients had low serum
YKL-40 levels and low BALF YKL-40 levels, i.e. values below
their respective cut-off points. None of these 10 patients
(0%) died from IPF during the follow-up period. Nine
patients were still alive while one patient had died from
a cause unrelated to IPF. In the intermediate group, either
the serum or BALF YKL-40 level was low (n Z 31). In this
group, 10 patients (32%) died from IPF while 21 were
censored. In contrast, 17 patients had both high serum and
high BALF YKL-40 levels and of these 11 patients had died
(65%).
Multivariate Cox regression analysis showed that the
average hazard ratio after correction for age, gender,
smoking, lung function blood and BALF cell counts was 4.8
(95%CI 1.5e15.3, p < 0.01).
Discussion
This study investigated YKL-40 as a potential biomarker for
prognosis in IPF.
In our cohort of IPF patients, high serum and BALF YKL-
40 levels were significantly associated with shorter survival
time (Fig. 4 A, B). Optimum cut-off points for serum and
BALF YKL-40 were determined using ROC-curve analysis and
stratifying patients according to these cut-off points
resulted in three groups with significantly different survival
estimates. In the group with both low serum and low BALF
YKL-40 levels, there were no IPF related deaths during the
4-year follow-up period (Fig. 4 C).significantly worse survival estimates than patients with low BALF
serum YKL-40 and low BALF YKL-40 there were no IPF related dea
serum YKL-40 and high BALF YKL-40 had significantly worse surviva
high BALF YKL-40 (p < 0.01, c2 Z 13.09).Multivariate Cox regression analysis showed that there
were no confounding factors in our survival analysis. In our
cohort, only age, BALF neutrophil percentage and smoking
were marginally associated with survival. Other IPF survival
studies have shown that age, smoking, and baseline clinical
parameters can be predictors for survival although findings
differ and are often contradictory.26e30 After correction
for possible confounding factors, the association between
serum and BALF YKL-40 levels and prognosis in IPF
remained significant. However, these findings will have to
be confirmed in an independent cohort.
The previously reported prognostic markers for IPF,
such as SP-D and CCL18, seem to be most predictive in the
first year after diagnosis.31,32 YKL-40 remains predictive
after 3e4 years and could thus be of use in a clinical
setting. In addition, combining YKL-40 with a short-term
prognostic biomarker may result in an even better esti-
mate of survival.
This is the first study to investigate the influence of
a CHI3L1 polymorphism on BALF YKL-40 levels. In IPF
patients, presence of the CHI3L1 e329 GG genotype resul-
ted in higher YKL-40 levels in BALF. We did not find
a significant difference in genotype frequency between
patients and controls and the  329 polymorphism there-
fore does not seem to influence IPF disease susceptibility.
The  329 genotype influences BALF YKL-40 levels and
thereby seems to cause an indirect effect on survival in IPF
patients. However, no significant difference in survival
curves was observed in our cohort. Further studies are
needed to determine if an effect of CHI3L1 genotype on
survival can be found when a larger cohort is used. The
 329 G-allele is almost in complete linkage disequilibrium
with the  131 C-allele, as was also previously found by
Ratcke et al.33 In recent studies, CHI3L1 e131 was found to
be associated with asthma and atopy,23,34,35 liver fibrosis22
and schizophrenia.36 The  131 CC genotype results in
higher serum YKL-40 levels and is associated with more
severe liver fibrosis and a predisposition to develop
asthma.22,23 However, no effects of this polymorphism on
the expression of YKL-40 in the lung have been reported.
Because of the large variation in serum and BALF YKL-40
levels in our cohort of IPF patients, determining the effect
of a genetic polymorphism on disease susceptibility and
progression will be hampered.
The study results suggest that the 329 genotype
neither predisposes to IPF nor influences activity of IPF.
YKL-40, a chitinase-like glycoprotein, is expressed in
many healthy tissues, and expression is higher in cells with
high metabolic activity.37 YKL-40 is also known to be
upregulated in late stages of macrophage differentiation.38
Furuhashi et al. showed that in lungs from IPF patients,
bronchiolar epithelial cells and alveolar macrophages near
areas of remodelling express YKL-40.16 This is the most
likely source of the elevated BALF YKL-40 levels found in
IPF patients. YKL-40 has been found to induce the releaseYKL-40 (P < 0.01, c2 Z 7.81). (C) In the group with both low
ths within 48 months after diagnosis. Patients with both high
l estimates than patients who had either high serum YKL-40 or
112 N.M. Korthagen et al.of profibrotic and proinflammatory cytokines by alveolar
macrophages and could thus contribute to tissue remodel-
ling in the lung.39
The source of serum YKL-40 is more difficult to ascer-
tain. Blood granulocytes are the most likely source,40 but
no significant correlation between serum YKL-40 and blood
granulocytes was found in our cohort. In addition, it is
unlikely that protein leakage through the damaged alveolar
walls is a major source of elevated serum levels, as the
correlation between BALF and serum YKL-40 levels is low.
The lack of correlation between serum and BALF YKL-40
levels might reflect different sources of the protein. In the
lung, alveolar macrophages and epithelial cells seem to be
the main source while the source of serum YKL-40 could be
specific subsets of peripheral immune cells.16,40,41 Our
results indicate that serum and BALF YKL-40 levels are
independently associated with survival and could therefore
also reflect different pathogenic processes. YKL-40 is
known to be upregulated in inflammatory conditions and it
could be a marker of peripheral immune cell activation,41
whereas BALF YKL-40 levels may be indicative of local
remodelling and macrophage activation. Activation
markers of circulating immune cells have been associated
with IPF progression.42 How this is a part of IPF pathology
and why peripheral YKL-40 production predicts disease
progression is still unclear and deserves further research.
YKL-40 is a marker for inflammation, tissue remodelling
and cancer and as such could simply reflect the pathogenic
process in IPF. YKL-40 has been shown to be a connective
tissue cell growth factor, to modulate collagen I fibrillo-
genesis, and angiogenesis, which are all involved in wound
repair.9,11,43 In vitro tests showed that YKL-40 is a growth
factor for fibroblasts and may therefore be directly
involved in the pathogenesis of fibrotic disorders.9 Mice
lacking the mouse equivalent of YKL-40 were found to
have significantly less IL13/TGF- b mediated tissue
inflammation and fibrosis.44 The elevated levels observed
in IPF patients in this study, and previously in a smaller
Japanese cohort,16 could thus mediate the fibrotic process
in the IPF lung.
In conclusion, understanding about the role of YKL-40 in
biological pathways is growing but its exact function is not
clear. It has been associated with inflammation, angiogen-
esis, extracellular matrix remodelling, and fibroblast
growth and could therefore play a role in disease aeti-
ology.12 Our study showed that serum and BALF YKL-40
levels in IPF patients are upregulated in a genotype
dependent manner. In addition, elevated serum and BALF
YKL-40 levels are associated with shorter survival time and
could be prognostic markers of survival in IPF.
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